NCT01989910View on ClinicalTrials.gov

Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2017

Conditions

HIV-1 Infection

Interventions

DRUG

Raltegravir

Raltegravir 400mg oral twice daily

DRUG

Efavirenz

Efavirenz 600mg oral at bedtime

Trial Locations (1)

11217

Division of Infectious Diseases, Taipei Veterans General Hospital, Taipei

All Listed Sponsors

lead

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

NCT01989910 - Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients | Biotech Hunter | Biotech Hunter